Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.61 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.48 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.46 |
| ▸ | TRPM8 | Q7Z2W7 | 2/20 | 0.46 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.44 |
| ▸ | EPHX1 | P07099 | 3/20 | 0.43 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10519642 | 0.92 | ALDH1A1 (0.65) | ALDH1A1LMNAKDM4EAPOBEC3AAPOBEC3G | |
| SCHEMBL15958908 | 0.91 | ALDH1A1 (0.56) | ALDH1A1LMNAKDM4EAPOBEC3AAPOBEC3G | |
| SCHEMBL13697528 | 0.87 | ALDH1A1 (0.59) | ALDH1A1LMNAKDM4EAPOBEC3AAPOBEC3G | |
| SCHEMBL8070812 | 0.85 | ALDH1A1 (0.75) | ALDH1A1LMNAKDM4EAPOBEC3AAPOBEC3G | |
| SCHEMBL28140415 | 0.84 | ALDH1A1 (0.69) | ALDH1A1LMNAKDM4EAPOBEC3AAPOBEC3G | |
| SCHEMBL3378961 | 0.83 | ALDH1A1 (0.63) | ALDH1A1LMNAKDM4EAPOBEC3AAPOBEC3G | |
| SCHEMBL16360067 | 0.83 | ALDH1A1 (0.63) | ALDH1A1LMNAKDM4EAPOBEC3AAPOBEC3G | |
| SCHEMBL16518811 | 0.83 | ALDH1A1 (0.63) | ALDH1A1LMNAKDM4EAPOBEC3AAPOBEC3G | |
| SCHEMBL74463 | 0.83 | ALDH1A1 (0.63) | ALDH1A1LMNAKDM4EAPOBEC3AAPOBEC3G | |
| SCHEMBL11776331 | 0.83 | ALDH1A1 (0.55) | ALDH1A1LMNAKDM4EAPOBEC3AAPOBEC3G |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 165 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3494996-B1 | ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 158P1D7 PROTEINS | AGENSYS INC (US) | 2026-04-15 | — | — | EP | disclosed |
| US-20260034234-A1 | ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 191P4D12 PROTEINS | AGENSYS, INC. (US) | 2026-02-05 | — | — | US | disclosed |
| US-20260000604-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING ANTI-191P4D12 ANTIBODY DRUG CONJUGATES AND METHODS OF USE THEREOF | AGENSYS, INC. (US) | 2026-01-01 | — | — | US | disclosed |
| US-12496353-B2 | Synergistic effects between auristatin-based antibody drug conjugates and inhibitors of the PI3K-AKT mTOR pathway | SEAGEN INC. (US) | 2025-12-16 | — | — | US | disclosed |
| EP-4604951-A1 | 1-(SULFONYL)-N-PHENYLPYRROLIDINE-2-CARBOXAMIDES DERIVATIVES AND USE THEREOF | AMIRA THERAPEUTICS, S.L. (ES) | 2025-08-27 | — | — | EP | disclosed |
| CN-111330016-B | Antibody Drug Conjugates (ADCs) that bind 158P1D7 protein | 艾更斯司股份有限公司 | 2025-03-25 | — | — | CN | disclosed |
| US-12257340-B2 | Pharmaceutical compositions comprising anti-191P4D12 antibody drug conjugates and methods of use thereof | AGENSYS, INC. (US) | 2025-03-25 | — | — | US | disclosed |
| EP-3581206-B1 | SYNERGISTIC EFFECTS BETWEEN AURISTATIN-BASED ANTIBODY DRUG CONJUGATES AND INHIBITORS OF THE P13K-AKT MTOR PATHWAY | SEAGEN INC (US) | 2024-12-25 | — | — | EP | disclosed |
| CN-111330017-B | Antibody Drug Conjugates (ADCs) that bind 158P1D7 protein | 艾更斯司股份有限公司 | 2024-11-26 | — | — | CN | disclosed |
| CN-113677364-B | Pharmaceutical compositions comprising anti-191P 4D12 antibody drug conjugates and methods of use thereof | 艾更斯司股份有限公司 | 2024-07-05 | — | — | CN | disclosed |
| CN-101903403-A | CD19 binding agents and uses thereof | SEATTLE GENETICS INC | 2010-12-01 | — | — | CN | disclosed |
| WO-2010111018-A1 | ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 24P4C12 PROTEINS | AGENSYS, INC. (US) | 2010-09-30 | — | — | WO | disclosed |
| US-20100215671-A1 | Combination Therapy With Antibody-Drug Conjugates | SEAGEN INC. | 2010-08-26 | — | — | US | disclosed |
| EP-2211885-A1 | COMBINATION THERAPY WITH ANTIBODY-DRUG CONJUGATES | Seattle Genetics, Inc. (US) | 2010-08-04 | — | — | EP | disclosed |
| EP-2211904-A2 | CD19 BINDING AGENTS AND USES THEREOF | Seattle Genetics, Inc. (US) | 2010-08-04 | — | — | EP | disclosed |
| US-20090136526-A1 | CD19 Binding Agents and Uses Thereof | SEATTLE GENETICS, INC. (US) | 2009-05-28 | — | — | US | disclosed |
| WO-2009052431-A2 | CD19 BINDING AGENTS AND USES THEREOF | SEATTLE GENETICS, INC. (US) | 2009-04-23 | — | — | WO | disclosed |
| WO-2009048967-A1 | COMBINATION THERAPY WITH ANTIBODY-DRUG CONJUGATES | SEATTLE GENETICS, INC. (US) | 2009-04-16 | — | — | WO | disclosed |
| WO-2008049651-A1 | PERFORMANCE-ENHANCED COSMETIC COMPOSITIONS WITH PURINE AND/OR PURINE DERIVATIVES | HENKEL AG & CO. KGAA (DE) | 2008-05-02 | — | — | WO | disclosed |
| WO-2005070911-A1 | TRANSACETALISATION PROCESS | MONASH UNIVERSITY (AU) | 2005-08-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12496353-B2 | Synergistic effects between auristatin-based antibody drug conjugates and inhibitors of the PI3K-AKT mTOR pathway | MTOR, RICTOR, PIK3R5 | ALDH1A1 3563/4885LMNA 4541/4885KDM4E 1696/4885 |
| US-20260000604-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING ANTI-191P4D12 ANTIBODY DRUG CONJUGATES AND METHODS OF USE THEREOF | CD44, CA12, H1-10 | ALDH1A1 3280/4885LMNA 4220/4885KDM4E 214/4885 |
| US-20090136526-A1 | CD19 Binding Agents and Uses Thereof | BCL6B, CD22, BCL6 | ALDH1A1 3639/4885LMNA 3277/4885KDM4E 1889/4885 |
| US-12257340-B2 | Pharmaceutical compositions comprising anti-191P4D12 antibody drug conjugates and methods of use thereof | TMED10, CD44, CA12 | ALDH1A1 3787/4885LMNA 4224/4885KDM4E 488/4885 |
| US-20100215671-A1 | Combination Therapy With Antibody-Drug Conjugates | BCL6, BCL3, CD22 | ALDH1A1 546/4885LMNA 3689/4885KDM4E 2224/4885 |
| US-20260034234-A1 | ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 191P4D12 PROTEINS | IGSF11, ARID2, DYNLL2 | ALDH1A1 1803/4885LMNA 4551/4885KDM4E 254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.